Disagreement over Biosecure Act pushed Shipley out of BIO 

Dispute over China policy precipitated the departure of Nick Shipley, BIO’s EVP and chief advocacy officer, BIO board members and staff told BioCentury. Shipley had been closely involved with BIO’s decision in February to oppose a Senate version of the Biosecure Act. He had counseled against the decision by BIO President and CEO John Crowley to reverse the trade association’s position and publicly endorse the Biosecure Act. In internal discussions at BIO, Shipley reflected concerns expressed by BIO member companies that losing access to Chinese CDMOs will disrupt ongoing clinical development programs and increase the costs and timelines for future programs.
Shipley had served as BIO’s EVP and chief advocacy officer since September 2021. His departure on April 5 came exactly a month after Crowley’s first day on the job at BIO. Prior to joining BIO, Shipley served as Vice President at PhRMA for almost nine years, and as legislative director for then-Rep. Jay Inslee, a Democrat from Washington state.

Terns Pharmaceuticals Inc. (NASDAQ:TERN), which is developing small molecules for cancer and obesity, hired Melita Sun Jung as CBO, effective April 22. Jung was CBO at Structure Therapeutics Inc. (NASDAQ:GPCR)...